Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vertex Pharmaceuticals

How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

While Vertex Pharmaceuticals has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks

Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect

Vertex Pharmaceuticals is set to unveil its Q1 results in the upcoming month, and analysts expect a double-digit drop in earnings.

Analysts Say 12 Stocks Will Profit Most From Trump's Reign

First-quarter earnings season is in full swing. But investors playing the long game want to know which S&P 500 companies will profit most.

Investors Business Daily

Stocks Flashing Renewed Technical Strength: Vertex Pharmaceuticals

Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 85.

Investors Business Daily

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

inkl

Read news from The Economist, FT, and more,
with one subscription

Stocks With Rising Relative Strength: Vertex Pharmaceuticals

Stocks With Rising Relative Strength: Vertex Pharmaceuticals

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

Vertex Pharmaceuticals Earns RS Rating Upgrade

Vertex Pharmaceuticals Earns RS Rating Upgrade

Vertex Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Composite Rating For Vertex Pharmaceuticals Rises To 96

Composite Rating For Vertex Pharmaceuticals Rises To 96

Vertex Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 94 the day before.

Investors Business Daily

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

FDA approves 1st new class of opioid-free painkillers in over 20 years

FDA approves 1st new class of opioid-free painkillers in over 20 years

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Investors Business Daily

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Vertex Pharmaceuticals Earnings Preview: What to Expect

With Vertex Pharmaceuticals gearing up to release its fourth-quarter earnings next month, analysts predict a single-digit drop in profit.

Investors Business Daily

Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday.

Investors Business Daily

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?

Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.

Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.

20 innovative breakthroughs that will transform your health

We recognize some of the most staggering, game-changing, life-improving developments of the year.

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.

Is Vertex Pharmaceuticals Stock Underperforming the Dow?

Despite Vertex Pharmaceuticals’ recent underperformance compared to the Dow Jones, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Investors Business Daily

Vertex Pharmaceuticals Shows Rising Relative Strength; Still Shy Of Key Benchmark

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

Five S&P 500 Stocks On This Elite IBD List Near Buy Points

Meta stock and Nvidia peer Broadcom are among among five S&P 500 stocks on IBD Leaderboard that are near buy points.

Investors Business Daily

Stock Market: Three Top Names In Buy Zones, One With Earnings Due

The stock market awaits reports from Home Depot, Disney and Cisco Systems. Cisco, Costco and Vertex are in buy zones.

People

120,822 stories

Matthew Harrison

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

SP Global Market Intelligence

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Pain Management

Places

278,384 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play